Praecis makes prostate submission
Praecis has submitted an NDA with the FDA for the prostate cancer treatment abarelix depot. This first-in-class drug avoids stimulating the secretion of testosterone, the hormone implicated in most prostate cancers. The company is also investigating the drug for the treatment of endometriosis.